{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:56:10Z","timestamp":1793213770532,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We investigated the efficacy and safety of apararenone (MT-3995), a non-steroidal compound with mineralocorticoid receptor agonist activity, in patients with stage 2 diabetic nephropathy (DN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study had two parts: a dose\u2013response, parallel-group, randomized, double-blind, placebo-controlled, multicenter, phase 2, 24-week study and an open-label, uncontrolled, 28-week extension study. Primary and secondary endpoints were the 24-week percent change from baseline in urine albumin to creatine ratio (UACR) and 24- and 52-week UACR remission rates. Safety parameters were changes from baseline in estimated glomerular filtration rate (eGFR) and serum potassium at 24 and 52\u00a0weeks, and incidences of adverse events (AEs) and adverse drug reactions (ADRs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the dose\u2013response period, 73 patients received placebo and 73, 74, and 73 received apararenone 2.5\u00a0mg, 5\u00a0mg, and 10\u00a0mg, respectively. As a percentage of baseline, mean UACR decreased to 62.9%, 50.8%, and 46.5% in the 2.5\u00a0mg, 5\u00a0mg, and 10\u00a0mg apararenone groups, respectively, at week 24 (placebo: 113.7% at week 24; all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 vs placebo). UACR remission rates at week 24 were 0.0%, 7.8%, 29.0%, and 28.1% in the placebo and apararenone 2.5\u00a0mg, 5\u00a0mg, and 10\u00a0mg groups, respectively. eGFR tended to decrease and serum potassium tended to increase, but these events were not clinically significant. AE incidence increased with dose while ADR incidence did not.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The UACR-lowering effect of apararenone administered once daily for 24\u00a0weeks in patients with stage 2 DN was confirmed, and the 52-week administration was safe and tolerable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>NCT02517320 (dose\u2013response study) and NCT02676401 (extension study)<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-020-01963-z","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T19:03:11Z","timestamp":1600974191000},"page":"120-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose\u2013response study and open-label extension study"],"prefix":"10.1007","volume":"25","author":[{"given":"Takashi","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Terata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Totsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Gotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12967-019-2016-y","volume":"17","author":"G Wang","year":"2019","unstructured":"Wang G, Ouyang J, Li S, Wang H, Lian B, Liu Z, et al. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. J Transl Med. 2019;17:264.","journal-title":"J Transl Med"},{"key":"1963_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.4009\/jsdt.52.679","volume":"52","author":"The Japanese Society for Dialysis Therapy","year":"2019","unstructured":"The Japanese Society for Dialysis Therapy. Current status of chronic dialysis therapy in Japan. J Jpn Soc Dial Ther. 2019;52:679\u2013754 (Article in Japanese).","journal-title":"J Jpn Soc Dial Ther"},{"key":"1963_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-014-1057-z","volume":"19","author":"M Haneda","year":"2015","unstructured":"Haneda M, Utsunomiya K, Koya D, Babazono T, Moriya T, Makino H, et al. A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Clin Exp Nephrol. 2015;19:1\u20135.","journal-title":"Clin Exp Nephrol"},{"key":"1963_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225\u201332.","journal-title":"Kidney Int"},{"key":"1963_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0168-8227(97)01386-7","volume":"35","author":"CD Agardh","year":"1997","unstructured":"Agardh CD, Agardh E, Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract. 1997;35:113\u201321.","journal-title":"Diabetes Res Clin Pract"},{"key":"1963_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"1963_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/diacare.17.5.420","volume":"17","author":"T Sano","year":"1994","unstructured":"Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17:420\u20134.","journal-title":"Diabetes Care"},{"key":"1963_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc06-1998","volume":"30","author":"H Makino","year":"2007","unstructured":"Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577\u20138.","journal-title":"Diabetes Care"},{"key":"1963_CR9","unstructured":"The Japan Diabetes Society. Japanese Clinical Practice Guideline for Diabetes 2019. Tokyo, Japan: Nankodo; 201. https:\/\/www.jds.or.jp\/modules\/publication\/index.php?content_id=4. Accessed 20 Jan 2020."},{"key":"1963_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49:355\u201364.","journal-title":"Hypertension"},{"key":"1963_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","volume":"45","author":"A Nishiyama","year":"2005","unstructured":"Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005;45:710\u20136.","journal-title":"Hypertension"},{"key":"1963_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complicat. 2017;31:758\u201365.","journal-title":"J Diabetes Complicat"},{"key":"1963_CR13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2215\/CJN.14751218","volume":"14","author":"S Ito","year":"2019","unstructured":"Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019;14:1161\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1963_CR14","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285\u201392.","journal-title":"J Hypertens"},{"key":"1963_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1963_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1681\/ASN.2007060693","volume":"19","author":"L Vogt","year":"2008","unstructured":"Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19:999\u20131007.","journal-title":"J Am Soc Nephrol"},{"key":"1963_CR17","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/s41440-019-0320-9","volume":"42","author":"A Sato","year":"2019","unstructured":"Sato A. Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect? Hypertens Res. 2019;42:1841\u20137.","journal-title":"Hypertens Res"},{"key":"1963_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1963_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1963_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/187152506775268776","volume":"4","author":"P Mulatero","year":"2006","unstructured":"Mulatero P, Milan A, Williams TA, Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem. 2006;4:75\u201391.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"1963_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3\u201315.","journal-title":"J Hypertens"},{"key":"1963_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/978-981-13-8871-2_15","volume":"1165","author":"A Shrestha","year":"2019","unstructured":"Shrestha A, Che RC, Zhang AH. Role of aldosterone in renal fibrosis. Adv Exp Med Biol. 2019;1165:325\u201346.","journal-title":"Adv Exp Med Biol"},{"key":"1963_CR23","doi-asserted-by":"publisher","first-page":"e13390","DOI":"10.1111\/apha.13390","volume":"228","author":"J Barrera-Chimal","year":"2020","unstructured":"Barrera-Chimal J, Jaisser F. Vascular and inflammatory mineralocorticoid receptors in kidney disease. Acta Physiol (Oxf). 2020;228:e13390.","journal-title":"Acta Physiol (Oxf)"},{"key":"1963_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459\u201369.","journal-title":"Nat Rev Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-020-01963-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T06:43:13Z","timestamp":1632465793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-020-01963-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-01963-z","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"26 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Takashi Wada has received advisory fees and lecture fees from Mitsubishi Tanabe Pharma Corporation. Masaya Inagaki, Toru Yoshinari, Ryuji Terata, Naoko Totsuka, Miki Gotou and Gaia Hashimoto are employees of Mitsubishi Tanabe Pharma Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"These studies were conducted in accordance with the ethical principles of the Helsinki Declaration, the Pharmaceutical and Medical Device Act and good clinical practice, and the study was approved by the Institutional Review Board of each participating study center. All study patients provided informed consent prior to the start of treatment. The studies were registered at ClincialTrials.gov under the identifier numbers NCT02517320 (dose\u2013response study) and NCT02676401 (extension study).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}}]}}